206 related articles for article (PubMed ID: 22202162)
1. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.
Nehs MA; Nucera C; Nagarkatti SS; Sadow PM; Morales-Garcia D; Hodin RA; Parangi S
Endocrinology; 2012 Feb; 153(2):985-94. PubMed ID: 22202162
[TBL] [Abstract][Full Text] [Related]
2. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
[TBL] [Abstract][Full Text] [Related]
3. Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.
Vanden Borre P; Gunda V; McFadden DG; Sadow PM; Varmeh S; Bernasconi M; Parangi S
Oncotarget; 2014 Jun; 5(12):3996-4010. PubMed ID: 24994118
[TBL] [Abstract][Full Text] [Related]
4. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.
Nehs MA; Nagarkatti S; Nucera C; Hodin RA; Parangi S
Surgery; 2010 Dec; 148(6):1154-62; discussion 1162. PubMed ID: 21134546
[TBL] [Abstract][Full Text] [Related]
5. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.
Nucera C; Porrello A; Antonello ZA; Mekel M; Nehs MA; Giordano TJ; Gerald D; Benjamin LE; Priolo C; Puxeddu E; Finn S; Jarzab B; Hodin RA; Pontecorvi A; Nose V; Lawler J; Parangi S
Proc Natl Acad Sci U S A; 2010 Jun; 107(23):10649-54. PubMed ID: 20498063
[TBL] [Abstract][Full Text] [Related]
6. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ndishabandi D; Ashry T; McCarthy M; Zhou Z; Amin S; Freeman GJ; Alessandrini A; Parangi S
Br J Cancer; 2018 Nov; 119(10):1223-1232. PubMed ID: 30327563
[TBL] [Abstract][Full Text] [Related]
7. A Combinatorial Strategy for Targeting
Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
[TBL] [Abstract][Full Text] [Related]
8. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
9. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
Husain A; Hu N; Sadow PM; Nucera C
Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429
[TBL] [Abstract][Full Text] [Related]
10. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
[TBL] [Abstract][Full Text] [Related]
11. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
12. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.
Antonello ZA; Nucera C
Oncogene; 2014 Nov; 33(47):5397-404. PubMed ID: 24362526
[TBL] [Abstract][Full Text] [Related]
13. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Brauner E; Gunda V; Vanden Borre P; Zurakowski D; Kim YS; Dennett KV; Amin S; Freeman GJ; Parangi S
Oncotarget; 2016 Mar; 7(13):17194-211. PubMed ID: 26943572
[TBL] [Abstract][Full Text] [Related]
14. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
15. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
17. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
[TBL] [Abstract][Full Text] [Related]
19. An in vivo mouse model of metastatic human thyroid cancer.
Zhang L; Gaskins K; Yu Z; Xiong Y; Merino MJ; Kebebew E
Thyroid; 2014 Apr; 24(4):695-704. PubMed ID: 24262022
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E inhibition in anaplastic thyroid cancer.
Rosove MH; Peddi PF; Glaspy JA
N Engl J Med; 2013 Feb; 368(7):684-5. PubMed ID: 23406047
[No Abstract] [Full Text] [Related]
[Next] [New Search]
